These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 10500044)

  • 21. Alpha4beta1 integrin mediates selective endothelial cell responses to thrombospondins 1 and 2 in vitro and modulates angiogenesis in vivo.
    Calzada MJ; Zhou L; Sipes JM; Zhang J; Krutzsch HC; Iruela-Arispe ML; Annis DS; Mosher DF; Roberts DD
    Circ Res; 2004 Mar; 94(4):462-70. PubMed ID: 14699013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p73 Overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis.
    Vikhanskaya F; Bani MR; Borsotti P; Ghilardi C; Ceruti R; Ghisleni G; Marabese M; Giavazzi R; Broggini M; Taraboletti G
    Oncogene; 2001 Nov; 20(50):7293-300. PubMed ID: 11704858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenovirus-mediated gene therapy with an antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice.
    Liu P; Wang Y; Li YH; Yang C; Zhou YL; Li B; Lu SH; Yang RC; Cai YL; Tobelem G; Caen J; Han ZC
    Leuk Res; 2003 Aug; 27(8):701-8. PubMed ID: 12801528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular mediators of angiogenesis in bladder cancer.
    Campbell SC; Volpert OV; Ivanovich M; Bouck NP
    Cancer Res; 1998 Mar; 58(6):1298-304. PubMed ID: 9515819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.
    Reiher FK; Volpert OV; Jimenez B; Crawford SE; Dinney CP; Henkin J; Haviv F; Bouck NP; Campbell SC
    Int J Cancer; 2002 Apr; 98(5):682-9. PubMed ID: 11920636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate.
    Doll JA; Reiher FK; Crawford SE; Pins MR; Campbell SC; Bouck NP
    Prostate; 2001 Dec; 49(4):293-305. PubMed ID: 11746276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors.
    Shimamura M; Nagasawa H; Ashino H; Yamamoto Y; Hazato T; Uto Y; Hori H; Inayama S
    Br J Cancer; 2003 Jan; 88(2):307-13. PubMed ID: 12610518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.
    Relf M; LeJeune S; Scott PA; Fox S; Smith K; Leek R; Moghaddam A; Whitehouse R; Bicknell R; Harris AL
    Cancer Res; 1997 Mar; 57(5):963-9. PubMed ID: 9041202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response of bovine endothelial cells to FGF-2 and VEGF is dependent on their site of origin: Relevance to the regulation of angiogenesis.
    Cavallaro U; Tenan M; Castelli V; Perilli A; Maggiano N; Van Meir EG; Montesano R; Soria MR; Pepper MS
    J Cell Biochem; 2001; 82(4):619-33. PubMed ID: 11500940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth.
    Fahmy RG; Dass CR; Sun LQ; Chesterman CN; Khachigian LM
    Nat Med; 2003 Aug; 9(8):1026-32. PubMed ID: 12872165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin.
    Vogel T; Guo NH; Krutzsch HC; Blake DA; Hartman J; Mendelovitz S; Panet A; Roberts DD
    J Cell Biochem; 1993 Sep; 53(1):74-84. PubMed ID: 8227183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.
    Presta LG; Chen H; O'Connor SJ; Chisholm V; Meng YG; Krummen L; Winkler M; Ferrara N
    Cancer Res; 1997 Oct; 57(20):4593-9. PubMed ID: 9377574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: implications for tumor angiogenesis.
    García-Quiroz J; Rivas-Suárez M; García-Becerra R; Barrera D; Martínez-Reza I; Ordaz-Rosado D; Santos-Martinez N; Villanueva O; Santos-Cuevas CL; Avila E; Gamboa-Domínguez A; Halhali A; Larrea F; Díaz L
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():215-22. PubMed ID: 24120914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An N-terminal 80 kDa recombinant fragment of human thrombospondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in vitro and tumor growth and angiogenesis in vivo.
    Noh YH; Matsuda K; Hong YK; Kunstfeld R; Riccardi L; Koch M; Oura H; Dadras SS; Streit M; Detmar M
    J Invest Dermatol; 2003 Dec; 121(6):1536-43. PubMed ID: 14675207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis.
    Schwarte-Waldhoff I; Volpert OV; Bouck NP; Sipos B; Hahn SA; Klein-Scory S; Lüttges J; Klöppel G; Graeven U; Eilert-Micus C; Hintelmann A; Schmiegel W
    Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9624-9. PubMed ID: 10944227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of neuroblastoma-induced angiogenesis by fenretinide.
    Ribatti D; Alessandri G; Baronio M; Raffaghello L; Cosimo E; Marimpietri D; Montaldo PG; De Falco G; Caruso A; Vacca A; Ponzoni M
    Int J Cancer; 2001 Nov; 94(3):314-21. PubMed ID: 11745408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis.
    Jia H; Lohr M; Jezequel S; Davis D; Shaikh S; Selwood D; Zachary I
    Biochem Biophys Res Commun; 2001 May; 283(2):469-79. PubMed ID: 11327725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New activity of spironolactone. Inhibition of angiogenesis in vitro and in vivo.
    Klauber N; Browne F; Anand-Apte B; D'Amato RJ
    Circulation; 1996 Nov; 94(10):2566-71. PubMed ID: 8921802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth.
    Filleur S; Courtin A; Ait-Si-Ali S; Guglielmi J; Merle C; Harel-Bellan A; Clézardin P; Cabon F
    Cancer Res; 2003 Jul; 63(14):3919-22. PubMed ID: 12873985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.